Having trouble accessing articles? Reset your cache.

FDA chasing Actos cancer signal

FDA is reviewing the safety of Actos pioglitazone from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) after interim data from a long-term trial showed

Read the full 222 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE